Abstract
Thyroid carcinoma arising from normal follicular cells is generally slow-growing with an excellent prognosis if competently resected. However, once the tumor dedifferentiates and becomes undifferentiated (anaplastic) carcinoma, it becomes one of the most aggressive malignancies. Such a polarized characteristic is quite unique yet typical of thyroid carcinoma. To date, many researchers have studied differences in the characteristics of thyroid carcinoma before and after dedifferentiation. In this review, the difference in cell proliferating activity and the expression of cell cycle modulators is addressed. Cell proliferating activity of undifferentiated carcinoma is definitely higher than that of differentiated carcinoma. However, expression of cell cycle modulators in thyroid carcinoma is often unique and even discrepant. Some negative modulators are diffusely expressed and reduced expression of some positive modulators can be observed in undifferentiated carcinoma. We described these interesting findings in thyroid carcinoma in this review.
Keywords: thyroid cancer, cell cycle, cell proliferation
Current Cancer Therapy Reviews
Title: Expression of Cell Cycle Regulators in Thyroid Neoplasms Originating from Follicular Cells
Volume: 1 Issue: 2
Author(s): Yasuhiro Ito
Affiliation:
Keywords: thyroid cancer, cell cycle, cell proliferation
Abstract: Thyroid carcinoma arising from normal follicular cells is generally slow-growing with an excellent prognosis if competently resected. However, once the tumor dedifferentiates and becomes undifferentiated (anaplastic) carcinoma, it becomes one of the most aggressive malignancies. Such a polarized characteristic is quite unique yet typical of thyroid carcinoma. To date, many researchers have studied differences in the characteristics of thyroid carcinoma before and after dedifferentiation. In this review, the difference in cell proliferating activity and the expression of cell cycle modulators is addressed. Cell proliferating activity of undifferentiated carcinoma is definitely higher than that of differentiated carcinoma. However, expression of cell cycle modulators in thyroid carcinoma is often unique and even discrepant. Some negative modulators are diffusely expressed and reduced expression of some positive modulators can be observed in undifferentiated carcinoma. We described these interesting findings in thyroid carcinoma in this review.
Export Options
About this article
Cite this article as:
Ito Yasuhiro, Expression of Cell Cycle Regulators in Thyroid Neoplasms Originating from Follicular Cells, Current Cancer Therapy Reviews 2005; 1 (2) . https://dx.doi.org/10.2174/1573394054021736
DOI https://dx.doi.org/10.2174/1573394054021736 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Animal Models of Xenobiotic Receptors
Current Drug Metabolism Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?
Current Medicinal Chemistry Cancer-associated Autoantibodies as Biomarkers for Early Detection and Prognosis is Cancer: An Update
Current Cancer Therapy Reviews Rhodanine as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry Effects and Role of Multikinase Inhibitors in Thyroid Cancer
Current Pharmaceutical Design Cloning, Expression and Characterization of Mouse (Mus musculus) Nicotinamide 5-Mononucleotide Adenylyltransferase-2
Medicinal Chemistry The Acute Phase Protein α1-Acid Glycoprotein: A Model for Altered Glycosylation During Diseases
Current Protein & Peptide Science Cabozantinib in Thyroid Cancer
Recent Patents on Anti-Cancer Drug Discovery Di / tri-Peptide Transporters as Drug Delivery Targets: Regulation of Transport Under Physiological and Patho-physiological Conditions
Current Drug Targets Evolving Important Role of Lutetium-177 for Therapeutic Nuclear Medicine
Current Radiopharmaceuticals Radionuclides Used in Nuclear Medicine Therapy – From Production to Dosimetry
Current Medical Imaging Medical Treatment of Primary, Secondary, and Tertiary Hyperparathyroidism
Current Drug Safety Integrating the Universe of Effector and Regulatory Immune Cell Subsets: An Emerging Role of Protein-Glycan Interactions
Current Immunology Reviews (Discontinued) Catechol-O-Methyltransferase and Alzheimer's Disease: A Review of Biological and Genetic Findings
CNS & Neurological Disorders - Drug Targets Estrogen Receptor Neurobiology and its Potential for Translation into Broad Spectrum Therapeutics for CNS Disorders
Current Molecular Pharmacology Imaging of Integrins as Biomarkers for Tumor Angiogenesis
Current Pharmaceutical Design Small Molecules for Immunomodulation in Cancer: A Review
Anti-Cancer Agents in Medicinal Chemistry Critical Residues in Hsp70 Nucleotide Binding Domain for Challenges in Drug Design
Current Proteomics ABT-450: A Novel Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
Current Medicinal Chemistry Interaction between Microbes and Host Intestinal Health: Modulation by Dietary Nutrients and Gut-Brain-Endocrine-Immune Axis
Current Protein & Peptide Science